Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

Fig. 1

Characteristics of hepatocellular carcinoma (HCC) patients in the 2 cohorts. a Kaplan-Meier survival analysis of HCC patients in the 2 cohorts. The median survival time of HCC patients who received hepatic arterial infusion chemotherapy (HAIC) and sorafenib was 12.0 months and 12.4 months, respectively. There were no significant survival differences between the two cohorts (log-rank test, P = 0.65). b Serum levels of 6 cytokines (IL-5, IL-8, CXCL9, PDGF-BB, TGF-α, and VEGF-A) were distributed similarly in the sera of HCC patients in cohorts 1 and 2

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us